Novel Protein Glycan Side-Chain Biomarker and Risk of Incident Type 2 Diabetes Mellitus | Zendy

Akintunde O. Akinkuolie | Zendy; Aruna D. Pradhan | Zendy; Julie E. Buring | Zendy; Paul M. Ridker | Zendy; Samia Mora | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Novel Protein Glycan Side-Chain Biomarker and Risk of Incident Type 2 Diabetes Mellitus

Author(s) -

Akintunde O. Akinkuolie,

Aruna D. Pradhan,

Julie E. Buring,

Paul M. Ridker,

Samia Mora

Publication year - 2015

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.115.305635

Subject(s) - medicine , type 2 diabetes mellitus , diabetes mellitus , biomarker , c reactive protein , hazard ratio , endocrinology , body mass index , quartile , type 2 diabetes , inflammation , gastroenterology , confidence interval , chemistry , biochemistry

Enzymatically glycosylated proteins partake in multiple biological processes, including glucose transport and inflammation. We hypothesized that a novel biomarker (GlycA) of N-acetyl methyl groups originating mainly from N-acetylglucosamine moieties of acute-phase glycoproteins is related to incident type 2 diabetes mellitus and compared it with high-sensitivity C-reactive protein.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research